Bellevue Group AG Invests $145,000 in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Bellevue Group AG bought a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) during the first quarter, Holdings Channel.com reports. The fund bought 3,300 shares of the company’s stock, valued at approximately $145,000.

Other hedge funds have also bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its holdings in shares of IDEAYA Biosciences by 13.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,052,500 shares of the company’s stock worth $177,825,000 after buying an additional 486,222 shares during the last quarter. StemPoint Capital LP bought a new position in IDEAYA Biosciences in the first quarter valued at $3,835,000. CANADA LIFE ASSURANCE Co raised its position in IDEAYA Biosciences by 120.7% during the first quarter. CANADA LIFE ASSURANCE Co now owns 11,099 shares of the company’s stock valued at $487,000 after purchasing an additional 6,069 shares in the last quarter. American International Group Inc. lifted its stake in IDEAYA Biosciences by 8.4% during the first quarter. American International Group Inc. now owns 32,430 shares of the company’s stock worth $1,423,000 after purchasing an additional 2,514 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC purchased a new position in shares of IDEAYA Biosciences in the 1st quarter worth about $214,000. 98.29% of the stock is currently owned by institutional investors.

IDEAYA Biosciences Trading Down 0.1 %

NASDAQ IDYA traded down $0.04 on Monday, hitting $42.35. The company’s stock had a trading volume of 256,305 shares, compared to its average volume of 918,814. The firm has a market cap of $3.21 billion, a P/E ratio of -21.09 and a beta of 0.86. IDEAYA Biosciences, Inc. has a 52-week low of $21.22 and a 52-week high of $47.74. The company’s 50-day simple moving average is $38.34 and its 200 day simple moving average is $41.27.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). IDEAYA Biosciences had a negative return on equity of 20.09% and a negative net margin of 483.05%. IDEAYA Biosciences’s revenue for the quarter was down 100.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.49) earnings per share. On average, research analysts forecast that IDEAYA Biosciences, Inc. will post -2.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IDYA has been the topic of a number of research reports. BTIG Research raised their price objective on IDEAYA Biosciences from $55.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, July 9th. Wedbush reissued an “outperform” rating and set a $54.00 price target (down from $56.00) on shares of IDEAYA Biosciences in a research note on Tuesday, July 16th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $63.00 price objective on shares of IDEAYA Biosciences in a research note on Monday, July 8th. Oppenheimer boosted their price target on shares of IDEAYA Biosciences from $53.00 to $60.00 and gave the stock an “outperform” rating in a research note on Monday, July 8th. Finally, Mizuho assumed coverage on IDEAYA Biosciences in a report on Monday, July 8th. They issued an “outperform” rating and a $50.00 price objective on the stock. Fourteen analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $52.92.

Insider Activity

In related news, CEO Yujiro S. Hata sold 34,433 shares of the company’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $41.81, for a total transaction of $1,439,643.73. Following the completion of the sale, the chief executive officer now owns 677,887 shares in the company, valued at $28,342,455.47. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, insider Michael Anthony White sold 28,500 shares of the business’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $36.24, for a total transaction of $1,032,840.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Yujiro S. Hata sold 34,433 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $41.81, for a total value of $1,439,643.73. Following the completion of the transaction, the chief executive officer now directly owns 677,887 shares in the company, valued at $28,342,455.47. The disclosure for this sale can be found here. Insiders sold a total of 119,644 shares of company stock worth $4,832,228 in the last quarter. 3.50% of the stock is owned by company insiders.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.